New lupus drug PIT565 enters human safety trials

NCT ID NCT06335979

Ongoing Disease control Sponsor: Novartis Pharmaceuticals Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jul 01, 2026 · Updated 2 times

Summary

This early-stage study tests a new drug called PIT565 in about 54 people with active lupus who have not gotten better with standard treatments. The main goal is to see if the drug is safe and how the body processes it. Participants will receive increasing doses of the drug and be closely monitored for side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for SYSTEMIC LUPUS ERYTHEMATOSUS (SLE) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

systemic lupus erythematosus

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

SYSTEMIC LUPUS ERYTHEMATOSUS (SLE)

Contacts and locations

Locations

Novartis Investigative Site

Beijing, 100191, China
Novartis Investigative Site

Beijing, 100730, China
Novartis Investigative Site

Berlin, 10117, Germany
Novartis Investigative Site

Mainz, 55131, Germany
Novartis Investigative Site

Budapest, H-1083, Hungary
Novartis Investigative Site

Szeged, 6725, Hungary
Novartis Investigative Site

Leiden, South Holland, 2333 CL, Netherlands
Novartis Investigative Site

Santiago Compostela, A Coruna, 15706, Spain
Novartis Investigative Site

Barcelona, 08035, Spain
Novartis Investigative Site

Madrid, 28034, Spain
Novartis Investigative Site

Bern, 3010, Switzerland

More trials for these conditions

Other studies related to the condition(s) this trial covers.